Researchers found a positive correlation between glioblastoma cell proliferation and lactate metabolic indicators. Based on this observation, the researchers developed a biomimetic formulation using targeted delivery agents for lactate metabolism-based synergistic therapy against glioblastoma brain cancer.
Researchers say the gut microbiome may be a viable targetable biomarker to improve immunotherapy responses in those with glioblastoma and a range of other cancers.
Study reveals the ZNF117 gene is a major regulator of glioblastoma tumor cells.
INSR, a protein essential for insulin activity, plays a critical role in stem cell longevity. Additionally, inactivating INSR in glioblastoma brain cancer stem cells inhibits the growth of primitive tumor forming cells.
Variations in the TSPO neuroinflammation-associated protein's structure correlates with worse survival outcomes for male glioblastoma brain cancer patients than females.
A novel helmet that generates a noninvasive oscillating magnetic field was able to reduce tumor mass by 31% in a glioblastoma brain cancer patient.
Combining αGITR antibodies with ICBs resulted in stronger survival benefits in mouse models of human glioblastoma brain cancer.
Glioblastoma can mimic the normal repair of white matter in the brain, causing the tumor to become less malignant. Additionally, a drug commonly prescribed for asthma can help suppress glioblastoma growth in mouse models.